Characteristics of tertiary lymphoid structures in primary cancers

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-9

  Goc, Jérémy ^a,b,c   Fridman, Wolf Herman ^a,b,c   Sautès Fridman, Catherine ^a,b,c   Dieu Nosjean, Marie Caroline ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adaptive immune response; Migration; Tertiary lymphoid structure; Tumor immunology; Vasculature

Indexed keywords

CD31 ANTIGEN; CXCL13 CHEMOKINE; INTERLEUKIN 16; L SELECTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW CELL; CANCER CELL; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; HUMAN; IMMUNOCOMPETENT CELL; LYMPHATIC SYSTEM; MEMORY T LYMPHOCYTE; MOLECULAR INTERACTION; PRIMARY TUMOR; STROMA CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84894514010     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26836     Document Type: Article

References (93)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j. cell.2011.02.013
2. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/ nrc3245
3. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7; PMID:18026089; http:// dx.doi.org/10.1038/nature06309
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/ nature10673
5. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006; 7:344-53; PMID:16550197; http://dx.doi.org/10.1038/ni1330
6. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 2012; 33:297-305; PMID:22622061; http://dx.doi.org/10.1016/j. it.2012.04.006
7. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6:205-17; PMID:16498451; http://dx.doi. org/10.1038/nri1786
8. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996; 183:1461-72; PMID:8666904; http://dx.doi.org/10.1084/ jem.183.4.1461
9. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, Goodrich S, Woodland DL, Lund FE, Randall TD. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10:927-34; PMID:15311275; http://dx.doi.org/10.1038/nm1091
10. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, Klonowski KD, Lefrançois L, Cauley LS, Harmsen AG, Lund FE, et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 2006; 25:643-54; PMID:17045819; http://dx.doi. org/10.1016/j.immuni.2006.08.022
11. Hjelmström P, Fjell J, Nakagawa T, Sacca R, Cuff CA, Ruddle NH. Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am J Pathol 2000; 156:1133-8; PMID:10751336; http:// dx.doi.org/10.1016/S0002-9440(10)64981-4
12. Carragher DM, Rangel-Moreno J, Randall TD. Ectopic lymphoid tissues and local immunity. Semin Immunol 2008; 20:26-42; PMID:18243731; http:// dx.doi.org/10.1016/j.smim.2007.12.004
13. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc Natl Acad Sci U S A 2007; 104:10577-82; PMID:17563386; http:// dx.doi.org/10.1073/pnas.0700591104
14. Cupedo T, Mebius RE. Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 2003; 15:243-8; PMID:15001173; http://dx.doi.org/10.1016/j. smim.2003.08.002
15. Ansel KM, Ngo VN, Hyman PL, Luther SA, Förster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406:309-14; PMID:10917533; http://dx.doi. org/10.1038/35018581
16. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000; 12:471-81; PMID:10843380; http://dx.doi.org/10.1016/ S1074-7613(00)80199-5
17. Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M, Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169:424-33; PMID:12077273
18. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi. org/10.1146/annurev.immunol.22.012703.104803
19. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72:3125-30; PMID:22721837; http://dx.doi.org/10.1158/0008-5472.CAN-11-4094
20. Bergomas F, Grizzi F, Doni A, Pesce S, Laghi L, Allavena P, Mantovani A, Marchesi F. Tertiary Intratumor Lymphoid Tissue in Colo-Rectal Cancer. Cancers 2011; 4:1-10; http://dx.doi.org/10.3390/ cancers4010001
21. McMullen TPW, Lai R, Dabbagh L, Wallace TM, de Gara CJ. Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp Immunol 2010; 161:81-8; PMID:20408858
22. Suzuki A, Masuda A, Nagata H, Kameoka S, Kikawada Y, Yamakawa M, Kasajima T. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J Pathol 2002; 196:37-43; PMID:11748640; http://dx.doi. org/10.1002/path.1018
23. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé JJ. Unique ectopic lymph nodelike structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011; 179:37-45; PMID:21703392; http://dx.doi.org/10.1016/j.ajpath.2011.03.007
24. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie J-J, Rochaix P, Girard J-P. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678-87; PMID:21846823; http://dx.doi. org/10.1158/0008-5472.CAN-11-0431
25. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190:1417-26; PMID:10562317; http://dx.doi.org/10.1084/jem.190.10.1417
26. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 2002; 169:1829-36; PMID:12165506
27. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http:// dx.doi.org/10.1172/JCI67428
28. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res 2003; 63:3275-80; PMID:12810659
29. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360
30. Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard J-P. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin ß-producing dendritic cells in human breast cancer. J Immunol 2013; 191:2001-8; PMID:23825314; http://dx.doi.org/10.4049/ jimmunol.1300872
31. Cipponi A, Mercier M, Seremet T, Baurain J-F, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72:3997-4007; PMID:22850419; http://dx.doi.org/10.1158/0008-5472.CAN-12-1377
32. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Tímár J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-69; PMID:17279413; http://dx.doi.org/10.1007/ s00262-007-0286-3
33. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I, Girard J-P. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology 2012; 1:829-39; PMID:23162750; http://dx.doi.org/10.4161/onci.20492
34. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012; 2:765; PMID:23097687; http://dx.doi. org/10.1038/srep00765
35. Barone F, Bombardieri M, Rosado MM, Morgan PR, Challacombe SJ, De Vita S, Carsetti R, Spencer J, Valesini G, Pitzalis C. CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 2008; 180:5130-40; PMID:18354239
36. Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P, Challacombe S, De Vita S, Valesini G, Spencer J, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome. J Immunol 2007; 179:4929-38; PMID:17878393
37. Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi. org/10.1200/JCO.2007.15.0284
38. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman W-H, Sautès-Fridman C, Dieu-Nosjean M-C. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011; 71:6391-9; PMID:21900403; http://dx.doi. org/10.1158/0008-5472.CAN-11-0952
39. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean M-C, Alifano M, Régnard J-F, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22; PMID:21708957; http://dx.doi. org/10.1158/0008-5472.CAN-10-4179
40. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean M-C, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res Off J Am Assoc Cancer Res 2013
41. Thaunat O, Patey N, Caligiuri G, Gautreau C, Mamani-Matsuda M, Mekki Y, Dieu-Nosjean M-C, Eberl G, Ecochard R, Michel J-B, et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J Immunol 2010; 185:717-28; PMID:20525884; http://dx.doi.org/10.4049/ jimmunol.0903589
42. Uzzan B, Nicolas P, Cucherat M, Perret G-Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64:2941-55; PMID:15126324; http://dx.doi.org/10.1158/0008-5472.CAN-03-1957
43. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere J-F, Benamouzig R, Breau J-L, Perret G-Y. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006; 94:1823-32; PMID:16773076; http://dx.doi.org/10.1038/ sj.bjc.6603176
44. Donnem T, Al-Saad S, Al-Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund L-T, Bremnes RM. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007; 13:6649-57; PMID:18006765; http://dx.doi. org/10.1158/1078-0432.CCR-07-0414
45. Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, Yokomise H. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 2008; 44:1057-67; PMID:18396396; http://dx.doi.org/10.1016/j. ejca.2008.03.012
46. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA nonsmall cell lung cancer. J Clin Pathol 2004; 57:591-7; PMID:15166262; http://dx.doi.org/10.1136/ jcp.2003.013508
47. Martinet L, Garrido I, Girard J-P. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology 2012; 1:789-90; PMID:22934284; http://dx.doi. org/10.4161/onci.19787
48. Moussion C, Girard J-P. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 2011; 479:542-6; PMID:22080953; http://dx.doi.org/10.1038/ nature10540
49. Girard J-P, Moussion C, Förster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 2012; 12:762-73; PMID:23018291; http://dx.doi.org/10.1038/nri3298
50. Chen Q, Wang W-C, Evans SS. Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 2003; 52:670-9; PMID:12920482; http://dx.doi. org/10.1007/s00262-003-0425-4
51. Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992; 52:4265-8; PMID:1638539
52. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181:811-6; PMID:7530765; http:// dx.doi.org/10.1084/jem.181.2.811
53. Kawamata N, Xu B, Nishijima H, Aoyama K, Kusumoto M, Takeuchi T, Tei C, Michie SA, Matsuyama T. Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung. Respir Res 2009; 10:97; PMID:19845971; http://dx.doi. org/10.1186/1465-9921-10-97
54. Xu B, Wagner N, Pham LN, Magno V, Shan Z, Butcher EC, Michie SA. Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by L-selectin/PNAd, alpha4beta1 integrin/ VCAM-1, and LFA-1 adhesion pathways. J Exp Med 2003; 197:1255-67; PMID:12756264; http://dx.doi. org/10.1084/jem.20010685
55. Miyasaka M, Tanaka T. Lymphocyte trafficking across high endothelial venules: dogmas and enigmas. Nat Rev Immunol 2004; 4:360-70; PMID:15122201; http://dx.doi.org/10.1038/nri1354
56. DeNucci CC, Mitchell JS, Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit Rev Immunol 2009; 29:87-109; PMID:19496742; http:// dx.doi.org/10.1615/CritRevImmunol.v29.i2.10
57. Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008; 29:514-22; PMID:18838302; http://dx.doi.org/10.1016/j. it.2008.08.003
58. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286:2098-102; PMID:10617422; http://dx.doi.org/10.1126/ science.286.5447.2098
59. Hamanishi J, Mandai M, Matsumura N, Baba T, Yamaguchi K, Fujii S, Konishi I. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells 2010; 28:164-73; PMID:19911426
60. Liang CM, Zhong CP, Sun RX, Liu BB, Huang C, Qin J, Zhou S, Shan J, Liu YK, Ye SL. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 2007; 81:9502-11; PMID:17567706; http://dx.doi. org/10.1128/JVI.00208-07
61. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165:1992-2000; PMID:10925282
62. Yang S-C, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380
63. Yang S-C, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. Intrapulmonary administration of CCL21 genemodified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006; 66:3205-13; PMID:16540672; http://dx.doi.org/10.1158/0008-5472.CAN-05-3619
64. Yousefieh N, Hahto SM, Stephens AL, Ciavarra RP. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2009; 2:59-67; PMID:19418243; http://dx.doi.org/10.1007/s12307-009-0021-z
65. GeurtsvanKessel CH, Willart MA, Bergen IM, van Rijt LS, Muskens F, Elewaut D, Osterhaus AD, Hendriks R, Rimmelzwaan GF, Lambrecht BN. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 2009; 206:2339-49; PMID:19808255; http://dx.doi.org/10.1084/ jem.20090410
66. Halle S, Dujardin HC, Bakocevic N, Fleige H, Danzer H, Willenzon S, Suezer Y, Hämmerling G, Garbi N, Sutter G, et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med 2009; 206:2593-601; PMID:19917776; http:// dx.doi.org/10.1084/jem.20091472
67. Muniz LR, Pacer ME, Lira SA, Furtado GC. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J Immunol 2011; 187:828-34; PMID:21666055; http://dx.doi.org/10.4049/jimmunol.1004233
68. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. Dissecting the human immunologic memory for pathogens. Immunol Rev 2011; 240:40-51; PMID:21349085; http://dx.doi. org/10.1111/j.1600-065X.2010.01000.x
69. Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Kurita R, Nakayama M, Nakazaki Y, Takayama K, Nakanishi Y, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSFtransduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother 2008; 57:1399-411; PMID:18286286; http://dx.doi.org/10.1007/ s00262-008-0476-7
70. Kanagawa N, Niwa M, Hatanaka Y, Tani Y, Nakagawa S, Fujita T, Yamamoto A, Okada N. CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma. Int J Cancer 2007; 121:2013-22; PMID:17621629; http://dx.doi.org/10.1002/ ijc.22908
71. Kang S, Xie J, Ma S, Liao W, Zhang J, Luo R. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 2010; 215:153-62; PMID:19450895; http://dx.doi. org/10.1016/j.imbio.2009.03.001
72. Okada N, Sasaki A, Niwa M, Okada Y, Hatanaka Y, Tani Y, Mizuguchi H, Nakagawa S, Fujita T, Yamamoto A. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther 2006; 13:393-405; PMID:16224496; http://dx.doi.org/10.1038/ sj.cgt.7700903
73. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008; 122:2286-93; PMID:18224687; http://dx.doi.org/10.1002/ ijc.23392
74. Qin X-J, Shi H-Z, Deng J-M, Liang Q-L, Jiang J, Ye Z-J. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 2009; 15:2231-7; PMID:19318474; http://dx.doi.org/10.1158/1078-0432.CCR-08-2641
75. Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, Cutting S, Ladell K, Wynn KK, Withers D, et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 2012; 72:5473-82; PMID:22962270; http://dx.doi. org/10.1158/0008-5472.CAN-12-1912
76. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125-38; PMID:18725522; http://dx.doi.org/10.1084/ jem.20080099
77. Kaser A, Dunzendorfer S, Offner FA, Ludwiczek O, Enrich B, Koch RO, Cruikshank WW, Wiedermann CJ, Tilg HB. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol 2000; 165:2474-80; PMID:10946273
78. Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, Center DM, Fabel H. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000; 162:105-11; PMID:10903228; http://dx.doi. org/10.1164/ajrccm.162.1.9908055
79. Parada NA, Center DM, Kornfeld H, Rodriguez WL, Cook J, Vallen M, Cruikshank WW. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 1998; 160:2115-20; PMID:9498748
80. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/ science.1203486
81. Kirk CJ, Hartigan-O'Connor D, Mulé JJ. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumorreactive T cells extranodally. Cancer Res 2001; 61:8794-802; PMID:11751401
82. Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TNM, Andersen MH, thor Straten P, Reisfeld RA, Becker JC. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother 2008; 57:85-95; PMID:17605009; http://dx.doi.org/10.1007/ s00262-007-0352-x
83. Schrama D, thor Straten P, Fischer WH, McLellan AD, Bröcker EB, Reisfeld RA, Becker JC. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14:111-21; PMID:11239444; http://dx.doi. org/10.1016/S1074-7613(01)00094-2
84. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/ onci.22009
85. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261-7; PMID:23579076; http://dx.doi. org/10.1016/j.coi.2013.03.004
86. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14:5220-7; PMID:18698040; http://dx.doi. org/10.1158/1078-0432.CCR-08-0133
87. Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011; 17:5247-56; PMID:21659461; http://dx.doi.org/10.1158/1078-0432.CCR-10-2805
88. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, Nelson BH. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18:3281-92; PMID:22553348; http:// dx.doi.org/10.1158/1078-0432.CCR-12-0234
89. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 2012; 1:1623-5; PMID:23264915; http://dx.doi.org/10.4161/ onci.21650
90. Thompson ED, Enriquez HL, Fu Y-X, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med 2010; 207:1791-804; PMID:20660615; http:// dx.doi.org/10.1084/jem.20092454
91. Wherry EJ. T cell exhaustion. Nat Immunol 2011; 12:492-9; PMID:21739672; http://dx.doi. org/10.1038/ni.2035
92. Aubert RD, Kamphorst AO, Sarkar S, Vezys V, Ha S-J, Barber DL, Ye L, Sharpe AH, Freeman GJ, Ahmed R. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A 2011; 108:21182-7; PMID:22160724; http://dx.doi.org/10.1073/pnas.1118450109
93. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi. org/10.1158/0008-5472.CAN-10-1322